[{"id":"f17e9f3e-aca2-40fd-9842-6769913d6623","acronym":"","url":"https://clinicaltrials.gov/study/NCT02520063","created_at":"2021-01-18T12:10:45.080Z","updated_at":"2025-02-25T15:42:33.018Z","phase":"Phase 1/2","brief_title":"Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer","source_id_and_acronym":"NCT02520063","lead_sponsor":"University of Alabama at Birmingham","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • HER-2 negative • HR positive + HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • HR positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • letrozole • carotuximab IV (ENV-105)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 02/23/2019","start_date":" 02/23/2019","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-12-27"},{"id":"a2a285a5-555c-4e53-ba89-bdb5efd56b1a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05401110","created_at":"2022-06-02T16:58:56.919Z","updated_at":"2024-07-02T16:35:12.049Z","phase":"Phase 1","brief_title":"Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05401110","lead_sponsor":"Karen Reckamp, MD, MS","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • carotuximab IV (ENV-105)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 09/15/2023","start_date":" 09/15/2023","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2024-04-02"},{"id":"06fa6d0c-d77a-44bd-bfad-6e5ced982114","acronym":"","url":"https://clinicaltrials.gov/study/NCT03181308","created_at":"2021-01-18T15:41:17.626Z","updated_at":"2024-07-02T16:36:43.875Z","phase":"Phase 1b","brief_title":"Study of Carotuximab (TRC105) Plus Nivolumab in Patients With Metastatic NSCLC","source_id_and_acronym":"NCT03181308","lead_sponsor":"Tracon Pharmaceuticals Inc.","biomarkers":" EGFR • PD-L1 • ROS1 • ALK1","pipe":"","alterations":" ","tags":["EGFR • PD-L1 • ROS1 • ALK1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • carotuximab IV (ENV-105)"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 11/09/2017","start_date":" 11/09/2017","primary_txt":" Primary completion: 07/22/2019","primary_completion_date":" 07/22/2019","study_txt":" Completion: 07/22/2019","study_completion_date":" 07/22/2019","last_update_posted":"2020-06-24"},{"id":"c9a4cec3-a91c-4bce-b61e-71cb0817eced","acronym":"","url":"https://clinicaltrials.gov/study/NCT01975519","created_at":"2021-01-18T08:59:39.076Z","updated_at":"2024-07-02T16:36:44.893Z","phase":"Phase 2a","brief_title":"A Phase 1B Dose-escalation and Phase 2a Study of Carotuximab (TRC105) in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma","source_id_and_acronym":"NCT01975519","lead_sponsor":"Tracon Pharmaceuticals Inc.","biomarkers":" ENG","pipe":"","alterations":" ","tags":["ENG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pazopanib • carotuximab IV (ENV-105)"],"overall_status":"Completed","enrollment":" Enrollment 111","initiation":"Initiation: 12/10/2013","start_date":" 12/10/2013","primary_txt":" Primary completion: 03/11/2019","primary_completion_date":" 03/11/2019","study_txt":" Completion: 03/11/2019","study_completion_date":" 03/11/2019","last_update_posted":"2020-05-20"},{"id":"01bd9776-4109-4734-9d40-8f7b153b539f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03780010","created_at":"2021-01-18T18:41:47.734Z","updated_at":"2024-07-02T16:36:54.192Z","phase":"Phase 1b","brief_title":"Study of TRC105 + Paclitaxel/Carboplatin and Bevacizumab in Patients With NSCLC","source_id_and_acronym":"NCT03780010","lead_sponsor":"Tracon Pharmaceuticals Inc.","biomarkers":" ALK1","pipe":"","alterations":" ","tags":["ALK1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • carboplatin • paclitaxel • carotuximab IV (ENV-105)"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 09/01/2015","start_date":" 09/01/2015","primary_txt":" Primary completion: 06/01/2019","primary_completion_date":" 06/01/2019","study_txt":" Completion: 06/01/2019","study_completion_date":" 06/01/2019","last_update_posted":"2019-10-28"},{"id":"f126f464-cd22-47b6-a106-83891f6a2732","acronym":"","url":"https://clinicaltrials.gov/study/NCT01326481","created_at":"2021-01-18T05:24:16.843Z","updated_at":"2024-07-02T16:37:01.637Z","phase":"Phase 1b","brief_title":"Open Label Dose-Finding Study of TRC105 Plus Capecitabine for Metastatic Breast Cancer","source_id_and_acronym":"NCT01326481","lead_sponsor":"Tracon Pharmaceuticals Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • carotuximab IV (ENV-105)"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 06/01/2011","start_date":" 06/01/2011","primary_txt":" Primary completion: 09/01/2014","primary_completion_date":" 09/01/2014","study_txt":" Completion: 12/01/2014","study_completion_date":" 12/01/2014","last_update_posted":"2019-03-18"},{"id":"48716b21-6535-4713-9a0f-a09659ac678b","acronym":"","url":"https://clinicaltrials.gov/study/NCT01306058","created_at":"2021-01-18T05:18:51.239Z","updated_at":"2024-07-02T16:37:03.540Z","phase":"Phase 1/2","brief_title":"Sorafenib and TRC105 in Hepatocellular Cancer","source_id_and_acronym":"NCT01306058","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ENG","pipe":"","alterations":" ","tags":["ENG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • carotuximab IV (ENV-105)"],"overall_status":"Completed","enrollment":" Enrollment 27","initiation":"Initiation: 02/11/2011","start_date":" 02/11/2011","primary_txt":" Primary completion: 06/01/2016","primary_completion_date":" 06/01/2016","study_txt":" Completion: 06/09/2017","study_completion_date":" 06/09/2017","last_update_posted":"2019-01-23"},{"id":"7a4e6051-5b4f-43d4-bc82-22829467963b","acronym":"","url":"https://clinicaltrials.gov/study/NCT01332721","created_at":"2021-01-18T05:25:58.887Z","updated_at":"2024-07-02T16:37:04.875Z","phase":"Phase 1b","brief_title":"Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors for Which Bevacizumab is Indicated","source_id_and_acronym":"NCT01332721","lead_sponsor":"Tracon Pharmaceuticals Inc.","biomarkers":" MUC16","pipe":"","alterations":" ","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • carotuximab IV (ENV-105)"],"overall_status":"Completed","enrollment":" Enrollment 38","initiation":"Initiation: 04/01/2011","start_date":" 04/01/2011","primary_txt":" Primary completion: 09/01/2012","primary_completion_date":" 09/01/2012","study_txt":" Completion: 12/01/2013","study_completion_date":" 12/01/2013","last_update_posted":"2018-12-05"},{"id":"e83e2110-b8f6-4e45-9f60-dacc41f4a6ee","acronym":"","url":"https://clinicaltrials.gov/study/NCT01727089","created_at":"2021-01-18T07:32:39.498Z","updated_at":"2024-07-02T16:37:07.431Z","phase":"Phase 2","brief_title":"Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer","source_id_and_acronym":"NCT01727089","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IL2","pipe":"","alterations":" ","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • carotuximab IV (ENV-105)"],"overall_status":"Completed","enrollment":" Enrollment 59","initiation":"Initiation: 11/01/2012","start_date":" 11/01/2012","primary_txt":" Primary completion: 08/08/2017","primary_completion_date":" 08/08/2017","study_txt":" Completion: 08/08/2017","study_completion_date":" 08/08/2017","last_update_posted":"2018-08-28"}]